Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial
Study context
- Population
- Adults with BMI ≥27 kg/m² and established CVD or CKD, and/or ≥2 weight-related complications or CVD risk factorstarget recruitment 4,935
- Planned comparison
- Survodutide vs placebo
- Primary endpoint
- Time to first 5-point MACE (adjudicated composite)
Methodological detailsphase 3, double-blind, placebo-controlled, parallel-group, event-driven, cardiovascular (CV) safety study, global, Currently enrolling
- Phase 3
- Double-blind
- Placebo-controlled
- Parallel-group
- Event-driven
- CV safety study
- Global
- Currently enrolling
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Fail. Published 23 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →